Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brivanib + irinotecan
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Brivanib + irinotecan is an investigational combination therapy composed of two small molecule drugs used primarily in the treatment of metastatic colorectal cancer and other gastrointestinal malignancies. Brivanib is an orally available prodrug that acts as a dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and fibroblast growth factor receptors 1 and 2 (FGFR-1/2), thereby blocking angiogenesis essential for tumor growth[5]. Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication in cancer cells, leading to cell death. The combination aims to target both tumor vasculature (via antiangiogenic effects) and directly induce cytotoxicity in proliferating tumor cells. This regimen has been evaluated in phase I/II clinical trials for metastatic colorectal cancer, particularly after failure of standard therapies[1][7][8]. Brivanib was developed by Bristol Myers Squibb.
- Brand names
- Camptosar
- Other names
- brivanib alaninate + irinotecan
02
Targets
TOP1 (DNA Topoisomerase I)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on brivanib + irinotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brivanib + irinotecan.